Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-06-30

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer.

PURPOSE: Randomized phase II trial to study the effectiveness of applying topical imiquimod before abnormal cervical cells are removed in preventing cervical cancer in patients who have recurrent or persistent cervical neoplasia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment

NCT05405270

Cervical High Grade Squamous Intraepithelial Lesion Cervical Intraepithelial Neoplasia Grade 2/3 CIN 2/3 +1 more

RECRUITING

Imiquimod Treatment of High-grade CIN

NCT02917746

Cervical Intraepithelial Neoplasia

UNKNOWN NA

Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

NCT02669459

Cervical Intraepithelial Neoplasia

UNKNOWN PHASE3

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

NCT02130323

Cervical Intraepithelial Neoplasia

COMPLETED PHASE2/PHASE3

Imiquimod Treatment of CIN Lesions

NCT02329171

Cervical Intraepithelial Neoplasia

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the chemopreventive efficacy of topical imiquimod followed by local ablative or excisional therapy vs ablative/excisional therapy alone in patients with recurrent or high-grade cervical intraepithelial neoplasia.
* Compare the toxicity of these regimens in these patients.
* Compare the quality of life of patients treated with these regimens.
* Determine the safety and tolerability of imiquimod in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, disease (primary vs recurrent or persistent), severity of dysplasia (grade I vs grade II vs grade III), current tobacco use (yes vs no), planned surgical procedure (excisional vs laser vs cryotherapy vs other), and time since first abnormal Pap smear, including pathology of ascus favor dysplasia (less than 1 year vs 1-3 years vs more than 3 years). Patients are randomized to one of two treatment arms.

* Arm I: Patients undergo ablative or excisional therapy.
* Arm II: Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy.

Quality of life is assessed at baseline, after last dose of study drug (arm II only), 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.

Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy.

PROJECTED ACCRUAL: A total of 66-152 (33-76 per treatment arm) will be accrued for this study within 18 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Precancerous Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ablative or excisional therapy

Patients undergo ablative or excisional therapy.

Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.

Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy.

Group Type OTHER

Ablative or excisional therapy

Intervention Type PROCEDURE

Ablative or excisional therapy + imiquimod

Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.

Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy.

Group Type EXPERIMENTAL

imiquimod

Intervention Type DRUG

Ablative or excisional therapy

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

imiquimod

Intervention Type DRUG

Ablative or excisional therapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed primary grade II or III cervical intraepithelial neoplasia (CIN) or persistent grade I-III CIN (dysplasia that is not new and requires treatment)
* Squamous cell lesions not involving endocervix by colposcopy OR colposcopy with negative cytobrush or endocervical curettage
* No untreated cervical or vaginal infection other than human papilloma virus
* No desire for hysterectomy as ablative therapy

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Life expectancy:

* At least 5 years

Other:

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after study
* HIV negative
* No AIDS
* No known hypersensitivity to imiquimod
* No latex allergy

PRIOR CONCURRENT THERAPY:

Other:

* No concurrent immunosuppressive therapy

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No